| Name | Title | Contact Details |
|---|
"Love of invention will never end." - Carl Benz Learn more about us as we continue to pioneer the future of driving excellence. Data privacy: mb4.me/provider_privacy Imprint: Mercedes-Benz AG Mercedesstraße 120 D-70372 Stuttgart Deutschland Tel.: +49 7 11 17-0 E-Mail: dialog.mb@mercedes-benz.com Vertreten durch den Vorstand: Ola Källenius (Vorsitzender), Jörg Burzer, Renata Jungo Brüngger, Sabine Kohleisen, Harald Wilhelm, Markus Schäfer, Britta Seeger Vorsitzender des Aufsichtsrats: Martin Brudermüller Handelsregister beim Amtsgericht Stuttgart, Nr. HRB 762873 Umsatzsteueridentifikationsnummer: DE321281763
YA Group is an international professional services organization with over 25 years of experience, specializing in forensic consulting, engineering, and risk mitigation. Headquartered in the United States, the company employs more than 700 professionals and operates globally. It has evolved from its origins as a property damage consulting firm and has expanded through strategic acquisitions and organic growth. The firm offers a range of services, including forensic engineering and architecture, planning and construction advisory, and risk mitigation. Their expertise covers evaluations of existing structures, project controls, and comprehensive risk reduction strategies. YA Group serves a diverse clientele, including federal agencies, municipalities, healthcare systems, and educational institutions, emphasizing strong partnerships and a commitment to integrity and professionalism. The company is affiliated with several industry organizations, enhancing its credibility and expertise in the field.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We are a full-service agency providing insurance in personal, business, bonding, farm, life, and flood. Our staff has over 400 years of experience. We pride ourselves on customer service and knowledge of the products we offer. Stop in to one of our North Dakota or Minnesota locations.